209 related articles for article (PubMed ID: 16480334)
1. Conversion of tolerogenic CD4-8- dendritic cells to immunogenic ones inducing efficient antitumor immunity.
Zhang X; Moyana T; Quereshi M; Xiang J
Cancer Biother Radiopharm; 2006 Feb; 21(1):74-80. PubMed ID: 16480334
[TBL] [Abstract][Full Text] [Related]
2. Optimal TLR9 signal converts tolerogenic CD4-8- DCs into immunogenic ones capable of stimulating antitumor immunity via activating CD4+ Th1/Th17 and NK cell responses.
Zhang X; Munegowda MA; Yuan J; Wei Y; Xiang J
J Leukoc Biol; 2010 Aug; 88(2):393-403. PubMed ID: 20466823
[TBL] [Abstract][Full Text] [Related]
3. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones.
Zhang X; Kedl RM; Xiang J
Biochem Biophys Res Commun; 2009 Feb; 379(4):954-8. PubMed ID: 19135981
[TBL] [Abstract][Full Text] [Related]
4. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
5. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
6. Potent CD4+ T-cell epitope P30 enhances HER2/neu-engineered dendritic cell-induced immunity against Tg1-1 breast cancer in transgenic FVBneuN mice by enhanced CD4+ T-cell-stimulated CTL responses.
Xie Y; Chen Y; Ahmed KA; Li W; Ahmed S; Sami A; Chibbar R; Tang X; Tao M; Xu J; Xiang J
Cancer Gene Ther; 2013 Oct; 20(10):590-8. PubMed ID: 24052129
[TBL] [Abstract][Full Text] [Related]
7. CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity.
Zhang X; Huang H; Yuan J; Sun D; Hou WS; Gordon J; Xiang J
J Immunol; 2005 Sep; 175(5):2931-7. PubMed ID: 16116179
[TBL] [Abstract][Full Text] [Related]
8. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
9. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
10. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
Hao S; Yuan J; Xiang J
J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150
[TBL] [Abstract][Full Text] [Related]
11. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
12. Targeting dendritic cells with antigen-containing liposomes: a highly effective procedure for induction of antitumor immunity and for tumor immunotherapy.
van Broekhoven CL; Parish CR; Demangel C; Britton WJ; Altin JG
Cancer Res; 2004 Jun; 64(12):4357-65. PubMed ID: 15205352
[TBL] [Abstract][Full Text] [Related]
13. GP120-specific exosome-targeted T cell-based vaccine capable of stimulating DC- and CD4(+) T-independent CTL responses.
Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Chibbar R; Wei Y; Liu Q; Xiang J
Vaccine; 2011 Apr; 29(19):3538-47. PubMed ID: 21406265
[TBL] [Abstract][Full Text] [Related]
14. Successful cancer vaccine therapy for carcinoembryonic antigen (CEA)-expressing colon cancer using genetically modified dendritic cells that express CEA and T helper-type 1 cytokines in CEA transgenic mice.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Ishida K; Primus FJ; Yamaue H
Int J Cancer; 2007 Feb; 120(3):585-93. PubMed ID: 17096339
[TBL] [Abstract][Full Text] [Related]
15. Immortalized dendritic cell line with efficient cross-priming ability established from transgenic mice harboring the temperature-sensitive SV40 large T-antigen gene.
Ebihara S; Endo S; Ito K; Ito Y; Akiyama K; Obinata M; Takai T
J Biochem; 2004 Sep; 136(3):321-8. PubMed ID: 15598888
[TBL] [Abstract][Full Text] [Related]
16. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma.
Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000
[TBL] [Abstract][Full Text] [Related]
17. [In vitro anti-tumor effect of CTL induced by HSP70-Id complex-modified dendritic cells].
Wang ZH; Ye Q; Hu ZQ; Ye ZQ; Yu X; Shen GX
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):481-5. PubMed ID: 17147108
[TBL] [Abstract][Full Text] [Related]
18. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
Liu Y; Huang H; Chen Z; Zong L; Xiang J
J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636
[TBL] [Abstract][Full Text] [Related]
19. CD4+ Th2 cells function alike effector Tr1 and Th1 cells through the deletion of a single cytokine IL-6 and IL-10 gene.
Ankathatti Munegowda M; Xu S; Freywald A; Xiang J
Mol Immunol; 2012 Jun; 51(2):143-9. PubMed ID: 22424785
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cells recruit T cell exosomes via exosomal LFA-1 leading to inhibition of CD8+ CTL responses through downregulation of peptide/MHC class I and Fas ligand-mediated cytotoxicity.
Xie Y; Zhang H; Li W; Deng Y; Munegowda MA; Chibbar R; Qureshi M; Xiang J
J Immunol; 2010 Nov; 185(9):5268-78. PubMed ID: 20881190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
